Begin, Amie

Begin, Amie was paid $602K by Medicaid between Nov 2018 and Dec 2024, across 8 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 64% of everything it billed.

33Billing provider infoBEGIN, AMIE
LYNN, MA 01901

33aNPI1205378593assigned 11/17/2016

33bProvider typePrimary Care Nurse Practitioner

28Total paid$602K

24GClaims9,006

24DCodes billed8

24AFirst – last monthNov 2018 – Dec 2024

Compared with peers

Next to other Primary Care Nurse Practitioner providers in Massachusetts

Rank by total paid#1 of 21

Median peer was paid$7K

This provider vs. median90×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2018	86	$5K
2019	655	$40K
2020	1,744	$113K
2021	1,606	$113K
2022	2,287	$147K
2023	1,759	$127K
2024incomplete	869	$56K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
99214	Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity	64%	4,221	2,234	$385K
80307	Drug test(s), presumptive, any number of drug classes; immunoassay	30%	4,090	2,146	$178K
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	3.6%	381	334	$22K
99213	Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity	2.4%	225	181	$15K
99212	Office or other outpatient visit for the evaluation and management of an established patient, straightforward	<1%	44	36	$2K
87389	Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies	<1%	13	13	$242.71
98966		<1%	19	17	$204.63
86803		<1%	13	13	$143.78

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.